Alcon Inc. (ALC)
$
78.76
Key metrics
Financial statements
Free cash flow per share
3.2276
Market cap
39 Billion
Price to sales ratio
3.8855
Debt to equity
0.2375
Current ratio
2.6015
Income quality
1.9155
Average inventory
2.4 Billion
ROE
0.0493
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The financial data pertains to the fiscal year 2024. During this period, the company incurred an income tax expense of $238,000,000.00 indicating its tax obligations. The net total of other income and expenses is -$157,000,000.00 reflecting non-core financial activities. Furthermore, the gross profit ratio is 0.56 reflecting the efficiency of the company's production and sales operations. The net income ratio is 0.10 reflecting the company's profitability margin. Alcon Inc. is dedicated to advancing eye care through its Surgical and Vision Care segments, offering a comprehensive range of products such as intraocular lenses, surgical equipment, diagnostic tools, contact lenses, and ocular health solutions. Founded in 1945 and headquartered in Geneva, Switzerland, Alcon is committed to innovation and quality, ensuring that healthcare professionals and patients benefit from its advanced technologies and eye care solutions. The stock is reasonably priced at $77.25 appealing to a broad range of investors. With a mid-range market capitalization of $38,951,666,293.00 the company is a steady performer. Additionally, the stock has an average trading volume of 2,121,744.00 indicating moderate liquidity. Alcon Inc. is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. The company’s strategic focus on enhancing vision care and developing advanced surgical solutions positions it as a vital contributor in the eye care market, meeting the diverse needs of eye care professionals and patients worldwide.
Is Alcon Inc. (ALC) a good investment?
Investing in Alcon Inc. (ALC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Alcon Inc. (ALC)'s stock forecast?
Analysts predict Alcon Inc. stock to fluctuate between $71.55 (low) and $99.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alcon Inc.'s market capitalization?
As of 2025-12-15, Alcon Inc.'s market cap is $38,951,666,293, based on 494,561,519 outstanding shares.
How does Alcon Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alcon Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Alcon Inc. pay dividends?
Alcon Inc. pays dividends. The current dividend yield is 0.36%, with a payout of $0.33 per share.
How can I buy Alcon Inc. (ALC) stock?
To buy Alcon Inc. (ALC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALC. Place an order (Market, Limit, etc.).
What is the best time to invest in Alcon Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alcon Inc. perform in the last earnings report?
Revenue: $9,911,000,000 | EPS: $2.06 | Growth: 4.04%.
Where can I find Alcon Inc.'s investor relations reports?
Visit https://www.alcon.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alcon Inc.?
You can explore historical data from here
What is the all-time high and low for Alcon Inc. stock?
All-time high: $101.10 (2024-09-12) | All-time low: $55.21 (2022-10-13).
What are the key trends affecting Alcon Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has issued a new report and revised its recommendation with respect to STAAR's merger with Alcon. ISS is now recommending that all STAAR stockholders vote “FOR” STAAR's amended merger agree.
benzinga.com
Yunqi Capital Limited, which holds a 5.1% stake in STAAR Surgical Company (NASDAQ: STAA), issued a letter to shareholders on Wednesday.
reuters.com
Swiss eyecare giant Alcon has lifted its bid to acquire Staar Surgical to $30.75 per share in cash, it said on Tuesday, valuing the medical technology firm at $1.6 billion.
seekingalpha.com
Alcon Inc. remains a global leader in eye care, benefiting from aging demographics and technological innovation, but faces valuation and growth headwinds. Recent M&A activity, including the pending STAAR Surgical deal, pressures near-term earnings and adds uncertainty, despite strategic fit. ALC shares have declined from highs, now trading at a more reasonable 25 times earnings, but growth is slowing, and valuation remains somewhat elevated.
seekingalpha.com
Alcon Inc. ( ALC ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Daniel Cravens - Vice President of Investor Relations David Endicott - CEO & Director Timothy Stonesifer - Senior VP & CFO Conference Call Participants Anthony Petrone - Mizuho Securities USA LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Kavya Deshpande - UBS Investment Bank, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew Miksic - Barclays Bank PLC, Research Division David Saxon - Needham & Company, LLC, Research Division Veronika Dubajova - Citigroup Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Jack Reynolds-Clark - RBC Capital Markets, Research Division David Adlington - JPMorgan Chase & Co, Research Division Presentation Operator Greetings, and welcome to the Alcon Third Quarter 2025 Earnings Call.
benzinga.com
Eye care firm Alcon Inc. (NYSE:ALC) on Tuesday reported third-quarter sales of $2.59 billion, up 6% year over year (up 5% constant currency), marginally missing the consensus of $2.60 billion.
wsj.com
Shares rose after the eye-care specialist reported an acceleration in sales growth and confirmed its annual outlook, reassuring on its prospects after two guidance cuts this year.
zacks.com
Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
businesswire.com
GENEVA--(BUSINESS WIRE)--Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds.
businesswire.com
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated.
See all news
